Send me real-time posts from this site at my email

April 20 - Trading List: Updates, Analyst Actions, Our Take - TGTX

TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald

Cantor Fitzgerald analyst Alethia Young raised the firm's price target on TG Therapeutics to $74 from $68 and keeps an Overweight rating on the shares. The company's recent data update showed that the ULTIMATE I and II trials hit on the primary endpoint of annualized relapse rate, and Young views the data as differentiating in MS, the analyst tells investors in a research note. Young thinks all evidence points to ublituximab being a very effective and safe therapy for relapsing MS treatment.

TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm's price target on TG Therapeutics to $89 from $79 and keeps a Buy rating on the shares citing the "mpressive" additional ULTIMATE I and II data following the top-line data last December.

Our Take:  "This remains our Top Pick and is currently well undervalued. A very strong buy and a future buy out candidate. Anything under $50 is a good buy, under $45 a steal."

$TGTX, TG Therapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so)!

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.


Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue